TrimGen Selected for National Institutes of Health (NIH)-Sponsored Trial to Determine Clinical Significance of Pharmacogenetic-Based Warfarin Dosing

SPARKS, MD--(Marketwire - February 26, 2009) -

TrimGen Corporation proudly announces that its FDA/510(k) approved eQ-PCR™ LC Warfarin Genotyping Kit has been selected for use in the NHLBI-sponsored Clarification of Optimal Anticoagulation through Genetics study (COAG). The purpose of this study is to determine whether a gene-based strategy will benefit patients who are at high risk for warfarin sensitivity.

This NIH-sponsored study is the largest prospective, multi-center, randomized clinical trial in the United States. TrimGen Corporation will contribute warfarin genotyping test kits for the trial, which is scheduled to begin next month. TrimGen supports the NIH in its efforts to improve personalized medicine and looks forward to providing cutting-edge technology to this much-anticipated trial.

Detailed information about the eQ-PCR™ LC Warfarin Genotyping Kit can be found at www.TrimGen.com.

About COAG

Further information about this trial (NCT00839657) can be found at: http://www.clinicaltrials.gov/ct2/show/NCT00839657

About TrimGen

TrimGen is a biotechnology company focused on developing nucleic acid-based diagnostics products. The company’s proprietary technologies, eQ-PCR™ and Shifted Termination Assay™ (STA), are highly sensitive detection methods used to identify target genes and SNPs at very low levels. The STA technology is a unique mutation enrichment process that has been recently applied for detection of drug resistant KRAS mutations in patients with colorectal cancer. Products in development include assays for leukemia, lymphoma, solid tumor, blood disorder and infectious diseases.